What is ORGO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.17B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ORGO?

P/E (TTM) is n/a and 52-week range is $1.25 to $7.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ORGO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ORGO?

The company profile lists revenue (TTM) near $457M, net income (TTM) near $-8.42B, EPS (TTM) near $-0.69 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Organogenesis Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Canton, Massachusetts, US, 128.7M shares outstanding, ISIN US68621F1021 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Organogenesis Holdings Inc

$ORGO

Health Care · Biotechnology

IR Run Scenarios

$1.29

+0.78%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Organogenesis Holdings, Inc. is a regenerative medical company, which engages in the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical and sports medicine markets. The company is headquartered in Canton, Massachusetts and currently employs 854 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of regenerative products to address patient needs across the continuum of care. Its wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier, cross-linked with extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types as a protective barrier and extracellular matrix scaffold. Its sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for the management of open wounds in a surgical setting.

Employees

854

Website

investors.organogenesis.com

IPO

2016-12-02

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)